ArticleDiscover oncology2026
Identification of potential clinical markers associated with prognosis of neuroblastoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study retrospectively analyzed the data of patients with neuroblastoma (NB) to explore the risk factors and independent risk factors affecting the prognosis of patients.
methodA retrospective analysis was conducted on the data of patients with NB diagnosed and treated at Children’s Hospital of Kunming Medical University from January 2014 to December 2024. Kaplan–Meier (KM) survival analysis and the Cox Proportional Hazards Model were used to ascertain the risk factors and to identify independent risk factors associated with overall survival (OS) and disease-free survival (DFS), respectively.
resultA total of 231 patients were retrospectively analyzed. The results of Cox Proportional Hazards Model showed that age, tumor volume of onset (TVO), LNF (lactate dehydrogenase-neuron specific enolase-ferritin), metastasis site, DNA ploidy, and recurrence were independent risk factors affecting the OS. TVO, lactate dehydrogenase (LDH), neuron specific enolase (NSE), ferritin, LNF, image-defined risk factors (IDRFs), metastasis site, and DNA ploidy were independent risk factors affecting the DFS of patients.
conclusionReliable biomarkers are crucial for effective patient stratification and personalized treatment strategies for NB. Early identification of high-risk patients and the initiation of aggressive treatment can help improve OS and DFS in patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.